Trial Profile
A Post-Marketing Surveillance, Multicenter, Open-Label, Dose-Titrating, 4-Week Study Evaluating The Efficacy, Tolerability And Safety Of Olmesartan Medoxomil 20 Mg In Combination With 12.5 Mg Of Hydrochlorothiazide In Subjects With Mild To Moderate Essential Hypertension.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Dec 2009
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil (Primary) ; Hydrochlorothiazide
- Indications Essential hypertension
- Focus Adverse reactions
- Sponsors Pfizer
- 15 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jul 2009 Actual patient number (1723) added as reported by ClinicalTrials.gov.
- 15 Jul 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.